One the biggest inquiries carried out into marketing practices in the drugs industry ended on Wednesday with Italian police asking for almost 5,000 people to be put on trial, including more than 4,000 doctors and at least 273 employees of the British pharmaceuticals giant, GlaxoSmithKline. Some face up to five years in jail if tried and convicted.
Italy's revenue guard, the Guardia di Finanza, said in a statement that GlaxoSmithKline (GSK) and its predecessor firm had spent euros 228 million (US$275.9 million) on "sweeteners" for doctors, pharmacists and others over four years to 2002. The alleged bribes ranged from cameras, computers and holidays to outright cash payments.
The Guardia di Finanza said GlaxoSmithKline "should be held responsible for corporate crime as its managers and other employees acted in the company's interest".
A spokesman for GSK said last night it had been "cooperating closely with the authorities to facilitate their investigations.
"GSK is committed to ensuring that all its business practices are of the highest standards and any breach of that is unacceptable," the spokesman added.
But a British-based pharmaceuticals analyst said on Wednesday the type of activity the Italian authorities allege to have uncovered is common practice among global drug companies.
"It goes on all over the world -- but in parts of Europe, these things are absolutely rife," he said. "For example, doctors may be given `research grants' -- but there are no limits on how they can spend them."
He cited cases in which doctors have been offered cars or holidays as inducements to prescribe a particular brand.
Italy's Adnkronos news agency reproduced what it said was a letter written by a GSK district manager contained in the 10,000 pages of evidence assembled by the Guardia di Finanza. The letter urged sales representatives to approach specialists directly to get them to prescribe a cancer drug produced by the company.
"The initiative can work well with oncologists who have congresses, investments from us ... and who have not given us anything in return," the district manager was quoted as writing.
Illicit incentives were said to have been disguised in the firm's accounts under the headings of "field selling," "other promotion" and "medical phase IV."
Of the 4,713 people from all parts of Italy facing charges, 4,440 are doctors. They include more than 2,500 family doctors and some 1,700 specialists.
The most serious accusations have been levelled at doctors, pharmacists and sales representatives alleged to have been involved in a program intended to promote Hycamtin, a drug mainly used in the treatment of lung and ovarian cancers.
In some cases, it is claimed, specialists received a pro rata cash payment based on the number of patients treated with the drug.
At a press conference yesterday, a senior revenue guard officer, Giovanni Mainolfi, estimated that the two-year investigation -- codenamed Operation Jupiter -- was costing GSK's Italian subsidiary euros 400 million a year in lost sales.
"In 2002, the firm had a turnover of around euros 1.5 billion. The following year, it lost more than 20 percent [of its sales], with a turnover cut back to euros 1.1 billion," he said.
Evidence gathered during the investigation has been passed to the chief prosecutor in Verona. He will decide whether to seek indictments from a judge.
Other drug firms are being investigated by revenue guard units based in Rome, Milan and Florence.
‘IN A DIFFERENT PLACE’: The envoy first visited Shanghai, where he attended a Chinese basketball playoff match, and is to meet top officials in Beijing tomorrow US Secretary of State Antony Blinken yesterday arrived in China on his second visit in a year as the US ramps up pressure on its rival over its support for Russia while also seeking to manage tensions with Beijing. The US diplomat tomorrow is to meet China’s top brass in Beijing, where he is also expected to plead for restraint as Taiwan inaugurates president-elect William Lai (賴清德), and to raise US concerns on Chinese trade practices. However, Blinken is also seeking to stabilize ties, with tensions between the world’s two largest economies easing since his previous visit in June last year. At the
Nearly half of China’s major cities are suffering “moderate to severe” levels of subsidence, putting millions of people at risk of flooding, especially as sea levels rise, according to a study of nationwide satellite data released yesterday. The authors of the paper, published by the journal Science, found that 45 percent of China’s urban land was sinking faster than 3mm per year, with 16 percent at more than 10mm per year, driven not only by declining water tables, but also the sheer weight of the built environment. With China’s urban population already in excess of 900 million people, “even a small portion
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
Beijing is continuing to commit genocide and crimes against humanity against Uyghurs and other Muslim minorities in its western Xinjiang province, U.S. Secretary of State Antony Blinken said in a report published on Monday, ahead of his planned visit to China this week. The State Department’s annual human rights report, which documents abuses recorded all over the world during the previous calendar year, repeated language from previous years on the treatment of Muslims in Xinjiang, but the publication raises the issue ahead of delicate talks, including on the war in Ukraine and global trade, between the top U.S. diplomat and Chinese